For the quarter ending 2026-01-31, PURE had -$236K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-01-31 | 2025-10-31 | 2025-07-31 |
|---|---|---|---|
| Net loss | -785 | -464 | -2,399 |
| Share-based compensation | 58 | 34 | 147 |
| Depreciation | - | 1 | - |
| Depreciation and amortization | 2 | - | 2 |
| Accounts receivable | -137 | -85 | 176 |
| Inventories | 7 | 96 | 85 |
| Prepaid expenses | -31 | 18 | -4 |
| Interest on note payable to related parties | 98 | 91 | 287 |
| Accounts payable and accrued liabilities | -139 | 117 | 205 |
| Net cash used in operating activities | -606 | -250 | -2,015 |
| Net proceeds from note payable to related parties | 370 | 350 | 2,000 |
| Net cash provided by financing activities | 370 | 350 | 2,000 |
| Net decrease in cash, cash equivalents, and restricted cash | -236 | 100 | -15 |
| Cash, cash equivalents, and restricted cash at beginning of period | 509 | 409 | 424 |
| Cash, cash equivalents, and restricted cash at end of period | 273 | 509 | 409 |
PURE BIOSCIENCE, INC. (PURE)
PURE BIOSCIENCE, INC. (PURE)